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In patients with limited exercise capacity and (relative) contraindications to direct vasodilators
such as dipyridamole or adenosine, dobutamine stress nuclear myocardial perfusion imaging
(DSMPI) represents an alternative, exercise-independent stress modality for the detection of
coronary artery disease (CAD). Nondiagnostic test results (absence of reversible perfusion
defects with submaximal stress) do occur in approximately 10% of patients. Serious side effects
during DSMPI are rare, with no death, myocardial infarction or ventricular fibrillation
reported in three DSMPI safety reports for a total of 2,574 patients. On the basis of a total
number of 1,014 patients reported in 20 studies, the sensitivity, specificity and accuracy of the
test for the detection of CAD were 88%, 74% and 84%, respectively. Mean sensitivities for
one-, two- and three-vessel disease were 84%, 95% and 100%, respectively. The sensitivity for
detection of left circumflex CAD (50%) was lower, compared with that for left anterior
descending CAD (68%) and right CAD (88%). The sensitivity of predicting multivessel
disease by multiregion perfusion abnormalities varied widely, from 44% to 89%, although
specificity was excellent in all studies (89% to 94%). In direct diagnostic comparisons, DSMPI
was more sensitive, but less specific, than dobutamine stress echocardiography and compa-
rable with direct vasodilator myocardial perfusion imaging. In the largest prognostic study,
patients with a normal DSMPI study had an annual hard event rate less than 1%. An ischemic
scan pattern provided independent prognostic value, with a direct relationship between the
extent and severity of the perfusion defects and prognosis. In conclusion, DSMPI seems a safe
and useful nonexercise-dependent stress modality to detect CAD and assess prognosis. (J Am
Coll Cardiol 2000;36:2017–27) © 2000 by the American College of Cardiology
Confirming or excluding coronary artery disease (CAD) in
patients with chest pain remains a challenge because this
disease is still the leading cause of death in the western
world (1). Traditionally, exercise stress testing is performed
as a first-line noninvasive diagnostic stress test (2). How-
ever, large numbers of patients referred for evaluation of
chest pain are unable to perform adequate exercise testing,
mainly because of deconditioning or neurologic, respiratory,
peripheral vascular or orthopedic limitations (3). In these
patients, pharmacological stress nuclear myocardial perfu-
sion imaging (MPI) represents an alternative, exercise-
independent stress modality. Usually, dipyridamole or aden-
osine is used as a stressor because of their superiority in
creating blood flow heterogeneity (4) and the extensive
experience with these stress modalities. For patients with
(relative) contraindications to these direct vasodilators, such
as severe obstructive airway disease (particularly patients
with active wheezing or recent hospitalization for an exac-
erbation), high-grade atrioventricular block, arterial hypo-
tension, ingestion of caffeine-containing beverages ,12 h
before testing or the use of dipyridamole or theophylline-
containing compounds or medications ,24 h before testing,
dobutamine stress myocardial perfusion imaging (DSMPI)
represents an alternative stress modality. Since its clinical
introduction in 1984, DSMPI is increasingly used for
detecting CAD and assessing prognosis (5–32). This review
article deals with the: 1) methodology, 2) feasibility and
safety, 3) diagnostic value for the detection of CAD and 4)
prognostic value of DSMPI.
METHODS AND STATISTICAL ANALYSIS
A Medline search on DSMPI (search terms dobutamine
and thallium or technetium) studies published in the major
English language journals until the end of 1998 was
performed. Studies were only included for diagnostic anal-
ysis if these studies included patients with and without
angiographically defined CAD and if it was stated how
many patients with and without CAD had negative and
positive DSMPI results. Reports indicating that the patients
included were subsets of larger published studies were
excluded. Also excluded from the primary diagnostic anal-
ysis were studies describing special issues, such as the value
of DSMPI in patients with left bundle branch block
(LBBB) or left ventricular hypertrophy (LVH) and studies
involving only patients with prior myocardial infarction
(MI). These subgroups were discussed separately. When
DSMPI was compared with other stress modalities, only
those studies making direct comparisons in the same pa-
tients were included.
Sensitivity was defined as the number of true positive
tests divided by the total number of patients with angio-
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graphically significant CAD. Specificity was defined as the
number of true negative tests divided by the total number of
patients without angiographically significant CAD. Accu-
racy was defined by the total number of true positive and
true negative tests divided by the total number of patients.
Mean values for sensitivity, specificity and accuracy were
calculated by combining the results of individual patient
data from multiple studies. Comparisons of sensitivity,
specificity and accuracy were performed using the standard-
ized normal distribution test. Statistical significance was
defined at p , 0.05.
TEST METHODOLOGY
Dobutamine: pharmacology and mechanism of action.
Dobutamine is a synthetic catecholamine with a relatively
short plasma half-life of approximately 2 min due to rapid
metabolization in the liver to inactive metabolites (33,34). It
has strong b1-receptor and mild a1- and b2-receptor ago-
nist activity. When used at low dose (up to 10 mg/kg body
weight per min), marked inotropic effects (mediated by both
a1- and b1-receptor stimulation) are encountered. These
effects are extensively used for treatment of heart failure and
the identification of dysfunctional, but viable, cardiac mus-
cle. When used at high-dose (up to 40 mg/kg/min), heart
rate is progressively increased (mediated by b1-receptor
stimulation). Despite a clear increase in cardiac output,
systemic blood pressure increases only minimally due to a
decrease in systemic vascular resistance because of peripheral
vasoconstrictive effects (mediated by a1-receptor stimula-
tion) overwhelmed by vasodilative effects (mediated by
b2-receptor stimulation). In patients without a sufficient
increase in heart rate, the addition of atropine has been
proposed to further increase heart rate by its vagolytic effects
(25,35). As a result of the hemodynamic changes, there is an
increase in oxygen demand resulting in a secondary dilation
of the coronary arteries and, thus, an increase in blood flow.
Additionally, dobutamine may also have a (minor) direct
vasodilatative effect on coronary vessels. For high-dose
dobutamine infusion, this increase in blood flow in normal
coronary arteries has been reported as three times baseline
(36). However, in myocardial regions supplied by a coronary
artery with a critical stenosis, the increase in oxygen demand
cannot be met by an adequate increase in blood flow (37).
For successful MPI, dobutamine should not only create an
adequate flow disparity between myocardial regions sup-
plied by normal and stenotic arteries, but the radionuclide
tracer (thallium-201 or technetium-99m) must be distrib-
uted in the myocardium in proportion to blood flow over the
range of flows induced by dobutamine also. Several studies
(4,38) have shown that dobutamine-induced cardiac
thallium-201 uptake expressed as a percentage of whole
body uptake is intermediate between exercise and direct
vasodilator stress and that heart-to-background ratios of
thallium-201 uptake are similar to direct vasodilator stress
(but less than exercise stress). Recently published studies on
dogs, however, reported that myocardial technetium-99m
uptake underestimated the relative blood flow deficit in-
duced by dobutamine, and it was suggested that dobutamine
adversely affects myocardial technetium-99m binding
(39,40).
Protocol. Protocols for DSMPI vary from institution to
institution, particularly with regard to dobutamine dose
(range 20 to 50 mg/kg/min), atropine addition (range 0 to
2 mg) and stage duration (range 3 to 5 min) (Table 1).
Usually, centers that use lower peak doses of dobutamine
(used mainly in the early reports) use longer infusion stage
durations and stop beta-adrenergic blocking agent treat-
ment more often before the test (Table 1). To date, the most
widely used protocol uses dobutamine up to 40 mg/kg/min,
with the addition of atropine up to 1 mg.
According to this protocol, a rest electrocardiogram
(ECG) is acquired; intravenous access is secured, and
dobutamine is then administered intravenously by an infu-
sion pump, starting at 10 mg/kg/min for 3 min, increasing
by 10 mg/kg/min every 3 min up to a maximum of 40
mg/kg/min. For patients not achieving 85% of their theo-
retical maximal heart rate (220 2 age) and without symp-
toms or signs of myocardial ischemia, atropine is adminis-
tered on top of the maximal dose of dobutamine starting
with 0.25 mg intravenously and repeated up to a maximum
of 1.0 mg within 4 min, with continuation of dobutamine
infusion. The radionuclide tracer should be injected at peak
heart rate, and dobutamine infusion should be continued for
at least 1 min. Throughout dobutamine infusion, the ECG
(3 leads) is continuously monitored and recorded (12 leads)
at 1-min intervals. Blood pressure is measured and recorded
by sphygmomanometry or automatic device every 3 min.
Reasons for interruption of the test are: horizontal or
downsloping ST segment depression .0.2 mV at an inter-
val of 80 ms after the J point compared with baseline, ST
segment elevation .0.1 mV in patients without a previous
MI, severe angina, a symptomatic reduction in systolic
blood pressure $40 mm Hg from baseline, hypertension
(blood pressure $240/120 mm Hg); significant tachyar-
rhythmias and any serious side effect was regarded as due to
dobutamine. A beta-adrenergic blocking agent that can be
injected intravenously must be available to reverse the effects
of dobutamine if they do not revert spontaneously and
quickly. For patients with obstructive airway disease (and in
Abbreviations and Acronyms
CAD 5 coronary artery disease
CI 5 confidence interval
DSE 5 dobutamine stress echocardiography
DSMPI5 dobutamine stress myocardial perfusion
imaging
ECG 5 electrocardiogram or electrocardiographic
LBBB 5 left bundle branch block
LVH 5 left ventricular hypertrophy
MI 5 myocardial infarction
MPI 5 myocardial perfusion imaging
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particular those with active wheezing), nitrates should be
preferred because the safety of even short-acting selective
beta-blockers was never demonstrated in these patients.
Contraindications to (high-dose) DSMPI include: critical
aortic stenosis, hypertrophic cardiomyopathy, uncontrolled
hypertension, uncontrolled atrial fibrillation, known severe
ventricular arrhythmias and disorders in potassium ho-
meostasis (41,42). The addition of atropine is contraindi-
cated for patients with narrow-angle glaucoma, myasthenia
gravis, obstructive uropathy or obstructive gastrointestinal
disorders.
Scintigraphic interpretation. Stress scintigraphic imaging
should take place immediately after the stress test with
thallium-201 and approximately 1 h after the stress test with
technetium-99m to optimize the scintigraphic images and
to prevent redistribution in the case of imaging with
thallium-201. To facilitate the interpretation and compari-
son of cardiac tomographic images, a standardized nomen-
clature and display of the images is recommended by the
Society of Nuclear Medicine (43). A positive test is denoted
by a completely or partially reversible perfusion defect, but,
sometimes, fixed perfusion defects are also used as a crite-
rion for CAD.
Other possible dobutamine stress-induced markers of
myocardial ischemia. ECG CHANGES. Whereas ST seg-
ment changes are the hallmark of ischemia in exercise tests
(2), they seem to have less value during dobutamine stress.
In an early study of patients with severe coronary lesions,
dobutamine stress-induced ST segment depression was
described as a highly sensitive and specific diagnostic test
(44). However, subsequent reports of patients with less
severe coronary lesions (8,11,18,22,45) could never confirm
the sensitivity of dobutamine stress-induced ST segment
depression for the detection of CAD. Whether this is due to
less stress (lower rate-pressure product compared with
exercise tests) or other factors, such as inclusion of patients
with abnormal baseline ECGs still needs to be established.
The specificity (and, thus, positive predictive value) of
dobutamine stress-induced ST segment depression, how-
ever, seems excellent, ranging from 88% to 93% (8,22,45).
Also, as in exercise testing (46), dobutamine stress-induced
ST segment elevation in patients without a previous MI was
consistently reported to be associated with (severe) CAD
(44,45,47).
SINUS NODE DECELERATION. Dobutamine stress-induced
sinus node deceleration, defined as an initial increase and
subsequent decrease in heart rate with progressive dobut-
amine infusion, occurs more often during dobutamine
infusion than during exercise (48–51). In a small DSMPI
study (49), it was reported to be a specific marker of
reversible inferior wall perfusion defects. Larger, dobut-
amine stress echocardiography (DSE) studies (50,51), how-
ever, found no clear relationship between dobutamine
stress-induced sinus node deceleration and inferior wall
motion abnormalities or right CAD. It was postulated thatTa
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cardiac slowing, in particular in combination with hypoten-
sion (see later), may also result from a neurally mediated
cardiovascular vasodepressor reflex (52,53). After exclusion
of ischemia (angina or ECG changes), it is our policy to
administer atropine to reverse sinus node deceleration.
HYPOTENSION. Generally, dobutamine stress causes an in-
crease in cardiac output and a reduction in systemic vascular
resistance (54,55) with a small increase in systolic blood
pressure as a net result (5–32). Although the pathophysiol-
ogy of dobutamine stress-induced hypotension has not been
completely defined, theoretically, it may result from: 1) an
inadequate increase in cardiac output to compensate for an
expected decrease in systemic vascular resistance or 2) a
disproportionate decrease in systemic vascular resistance in
the presence of a normal increase in cardiac output. An
inadequate increase in cardiac output may be due to inad-
equate contractile reserve, severe ischemic left ventricular
dysfunction or left-sided obstructive heart disease. Dynamic
left ventricular cavity obliteration due to strong inotropic
stimulation was proposed as an important cause for reduced
cardiac output and hypotension (56), especially in patients
with dehydration. Later studies could not confirm this
mechanism (57), and the proposed bolus of saline before
dobutamine infusion (56,58) did not prevent cavity obliter-
ation in a canine model (59). The second mechanism, a
disproportionate decrease in systemic vascular resistance,
may be due to excessive sensitivity of the peripheral circu-
lation to b2-receptor stimulation, increased b2-receptor
density (deconditioned patients) or a neurally mediated
mechanism in which vigorous myocardial contraction stim-
ulates the intramyocardial mechanoreceptors, resulting in
sympathetic withdrawal and enhanced parasympathetic ac-
tivity, the Bezold-Jarisch reflex (53). In contrast with
exercise stress-induced hypotension (60), all presently avail-
able data indicate that there is no relation between dobut-
amine stress-induced hypotension and reversible perfusion
defects (61), ischemic left ventricular systolic dysfunction
(55,57,62,63) or angiographically detected CAD (61,62).
After discontinuation of dobutamine infusion and putting
the patient in a Trendelenburg position, active treatment
(apart as described earlier) with infusion of fluids is rarely
required.
FEASIBILITY AND SAFETY
Approximately 10% of DSMPI tests are nondiagnostic
(defined as absence of reversible perfusion defects in sub-
maximal tests) because of an insufficient hemodynamic
response to dobutamine-atropine or limiting side effects
(7,29). Noncardiac side effects (nausea, headache, chills,
urgency and anxiety) are not uncommon but are usually well
tolerated, without the need for test termination. The most
common cardiovascular side effects are angina, hypotension
and cardiac arrhythmias. Although angina occurs in approx-
imately 25% of patients (7), severe angina as a test end point
without accompanying reversible perfusion defects is rare.
Dobutamine stress-induced hypotension (defined as a
$20 mm Hg decrease in systolic blood pressure) occurs in
approximately 15% of patients (5,7,61). Severe, symptom-
atic hypotension necessitating test termination, however,
occurs only rarely. Minor cardiac arrhythmias, such as
premature atrial or ventricular contractions, often occur, and
supraventricular and ventricular tachycardias occur each in
approximately 4% of patients (5–7) (Table 2). Supraventric-
ular tachycardias may be controlled with the injection of a
beta-blocker or (in patients with obstructive airway disease)
verapamil. Of note, digoxin (although often used) is, in our
opinion, not indicated for the acute management of atrial
fibrillation because of a delayed onset of action. Ventricular
tachycardias are usually nonsustained and have been attrib-
uted to b1-receptor stimulation and dobutamine-induced
reduction in plasma potassium concentrations (42). These
arrhythmias are more frequently seen in patients with a
history of previous ventricular arrhythmias (6,64) or markers
for left ventricular dysfunction such as (extensive) fixed
perfusion defects (7) or baseline wall motion abnormalities
(64). No study has reported an association between ventric-
ular tachycardias and the addition of atropine (64) or
reversible perfusion defects (7). Sustained ventricular tachy-
cardias may be managed with an injection of a beta-blocker
or lidocaine. In the case of hemodynamic instability, elec-
trical cardioversion is indicated. In three major DSMPI
safety reports (5–7) for a total of 2,574 patients, no patient
suffered death, MI or ventricular fibrillation, although, in a
DSE review on safety, sporadic cases of MI or ventricular
fibrillation were described (65). It should be recognized that
these severe complications can occur up to 20 min after
dobutamine withdrawal (66), and it has been suggested that,
in these patients, a1-mediated coronary and systemic vaso-
constriction might be paradoxically exacerbated, not re-
versed, by beta-blocker administration. Atropine intoxica-
tion (a central anticholinergic syndrome causing confusion
or sedation, treated by physostigmine 0.5 to 2.0 mg intra-
venously), although generally requiring a dose of atropine of
at least 5 mg (67), has been reported during DSE in a few
patients receiving #1 mg of atropine (66).
Table 2. Safety Reports on Dobutamine Stress Myocardial
Perfusion Imaging
Dakik
(5)
Hanson
(6)
Elhendy
(7)
Dobutamine dose
(mg/kg/min)
40 40 40 1 atropine
Number of patients 1,012 486 1,076
Complications
Death/MI/VF 0% 0% 0%
Ventricular tachycardia
sustained 0% 0% 0.1%
nonsustained 4.2% 6.0% 3.7%
Supraventricular tachycardia
atrial tachycardia NA 4.7% 3.5%
atrial fibrillation of flutter 1.2% 1.2% 0.9%
MI 5 myocardial infarction; NA 5 not available; VF 5 ventricular fibrillation.
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DIAGNOSTIC VALUE
Detection of CAD. As with other tests for detection of
CAD, the diagnostic accuracy of DSMPI is expressed by its
sensitivity and specificity. These indexes depend on the
presence of referral bias (coronary arteriography may be
guided by stress test results) and several technical factors
such as the stress protocol, the radiotracer (thallium-201 or
technetium-99m), the imaging technique (planar or single-
photon emission computed tomography), the definition of a
positive test and the threshold for defining significant CAD.
In addition, several characteristics of the patients studied
may affect these indexes, such as the presence or absence of
MI, the use of beta-blockers, the number of male patients,
the presence of collaterals, the type of lesion and the severity
(percentage stenosis) and extent (number of diseased ves-
sels) of CAD.
The reported sensitivity, specificity and accuracy for each
of the 20 diagnostic studies identified by Medline search
(8–27) are shown in Table 1. The overall (weighted mean)
sensitivity, specificity and accuracy of DSMPI for a total of
1,014 patients was 88% (95% confidence interval [CI] 86 to
90), 74% (95% CI 71 to 77) and 84% (95% CI 81 to 86),
respectively (Fig. 1).
Different reports from center to center are most likely due
to the aforementioned factors, in particular the stress
protocol and the use of beta-blockers. In the eight studies
(12,19,21,22,24–27) that used 40 mg dobutamine with
atropine, sensitivity for the detection of CAD was higher
compared with the six studies (13–15,17,20,23) that used
40 mg dobutamine without atropine (90% vs. 82%, p ,
0.02), without a loss in specificity. This finding was also
confirmed in the only study directly comparing the diag-
nostic accuracy of DSMPI with, versus without, atropine in
the same patients (25). The use of atropine is especially
recommended for patients using beta-blockers. These latter
medications lower the chronotropic and inotropic response
(and, thus, peak cardiac workload) during dobutamine stress
(18,68,69) and, thus, have the potential to lower the
sensitivity of the test (70,71).
The effect of the number of diseased coronary arteries was
assessed in nine studies (9,11,15–17,20,22,24,25) for a total
of 311 patients. Mean sensitivity increased significantly
from 84% for single-vessel disease to 95% for double-vessel
disease and to 100% for triple-vessel disease (Fig. 2).
Bayesian analysis. Although values for sensitivity and
specificity have a useful role, the use of DSMPI in diagnos-
tic practice is to assist in the clinical recognition of CAD. In
this sense, tests are used to reclassify the initial clinical
impression of the probability of CAD into high-, low- and
intermediate-risk subgroups. According to the Bayes theo-
rem, the likelihood of a positive test result is determined by
the probability of CAD in the patient studied, as well as the
accuracy of the test (72). In one report (73) that included
223 patients without a previous MI, the study cohort was
grouped into those with a high- (.80%), intermediate-
(10% to 80%) and low-probability (,10%) of CAD before
and after DSMPI, and the ability of DSMPI to restratify
patients was analyzed. According to the pretest likelihood of
CAD, 68 patients (30%) were regarded as having a “diag-
nostic” low- or high-probability of CAD. By application of
the Bayes theorem, DSMPI defined 97 patients (43%) as
being in the high or low posttest probability groups.
Importantly, the accuracy of predicting CAD in the high-
probability group and the absence of CAD in the low-
probability group after DSMPI was excellent (91%).
Detection of disease in individual coronary arteries. The
coronary arteries and their branches supply different regions
of the left ventricular myocardium. Based on the known
anatomic relationship between coronary arteries and various
myocardial regions, general guidelines have been developed
for the assignment of these myocardial regions to specific
coronary arteries. It is, therefore, possible to infer disease of
Figure 1. Sensitivity, specificity and accuracy of dobutamine stress myocardial perfusion imaging for the detection of CAD.
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a given coronary artery by noting the location of the
perfusion abnormalities. Figure 3 summarizes the sensitivity
and specificity for the identification of disease in the left
anterior descending, left circumflex and right coronary
arteries. The mean reported sensitivities, as assessed in seven
studies (11,15–17,19,24,25) for a total of 333 patients, were
68%, 50% and 88%, respectively, and the mean specificities
were 90%, 94% and 81%, respectively. Specificity for detec-
tion of right CAD was lower than that for left anterior
descending CAD (p , 0.02) and left circumflex CAD (p ,
0.0001). Sensitivity for detection of left circumflex CAD
was lower than that for left anterior descending CAD (p ,
0.005) and right CAD (p , 0.0001). The lower sensitivity
for detection of disease in the left circumflex artery may be
related to variation in coronary anatomy with a small
circumflex territory in some patients.
Identification of extensive CAD. An important goal of
noninvasive stress testing is the identification of patients
with left-main or three-vessel CAD. Such patients could
benefit from revascularization from a prognostic point of
view (74). Patients with multivessel CAD can be differen-
tiated from patients with single-vessel CAD by detection of
perfusion abnormalities in two or more coronary territories.
Investigators who examined the prediction of multivessel
CAD by this method (11,17,25,26) consistently reported a
high specificity (range 89% to 94%). However, the sensitiv-
ity of DSMPI for the prediction of multivessel CAD varied
markedly from 44% to 89%. Several factors may contribute
Figure 2. Sensitivity of dobutamine stress myocardial perfusion imaging for detection of CAD by number of diseased vessels.
Figure 3. Sensitivity (open bars) and specificity (solid bars) of dobutamine stress myocardial perfusion imaging for detection of CAD in individual coronary
arteries. Numbers within bars indicate number of vessels. Included in the analysis were patients with single-vessel and multivessel CAD disease. CAD 5
coronary artery disease; LAD 5 left anterior descending coronary artery; LCx 5 left circumflex coronary artery; RCA 5 right coronary artery. Only the
p values for sensitivity are displayed.
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to the underestimation of multivessel CAD: inadequate
stress protocols, the premature cessation of stress because of
the development of limiting angina, imperfect assignment
of myocardial perfusion regions to coronary arteries, collat-
eral circulations and anatomically significant, but function-
ally nonsignificant, lesions.
Comparison with other stress modalities in patients with
limited exercise capacity. DSE. In myocardial regions sup-
plied by a coronary artery with a significant stenosis,
dobutamine stress-induced increase in oxygen demand may
result in regional ischemia resulting in wall motion abnor-
malities that can be detected by two-dimensional echocar-
diography (65). In eight studies (11–13,17,21,22,24,26)
comparing DSMPI with DSE in the same 593 patients,
sensitivity was 86% versus 80% (p , 0.05); specificity was
73% versus 86% (p , 0.005), and accuracy was 82% versus
82% (Fig. 4). The finding that DSMPI is more sensitive
(especially in patients with single-vessel CAD) is in line
with the “ischemic cascade” theory (75), which states that
perfusion abnormalities due to limited coronary flow reserve
precede wall motion abnormalities.
VASODILATOR PERFUSION SCINTIGRAPHY. Direct vasodila-
tors (adenosine or dipyridamole) are considered to be the
most effective drugs to create coronary blood flow hetero-
geneity (4,37,38). Indeed, one study (76) reported that
dipyridamole MPI correlated better than DSMPI with a
“coronary extent score.” However, these results were based
on a small group of patients, and the dobutamine dose used
was extremely low. Only two studies (26,77) reported the
diagnostic accuracy of DSMPI versus direct vasodilator
MPI for the detection of CAD in the same patients. In
these two studies in 157 patients, sensitivity was 84% versus
90%; specificity was 77% versus 78%, and accuracy was 81%
versus 85%. Although there is no clear evidence for a
superiority of direct vasodilator MPI over DSMPI, the use
of the former as the drug of choice for MPI in patients with
limited exercise capacity seems reasonable on the basis of
theoretical grounds, diagnostic accuracy and extensive ex-
perience. However, it should be recognized that in the U.S.
(unlike Europe) direct vasodilators (and in particular aden-
osine) are very expensive in comparison with dobutamine.
Whether DSMPI is a more cost-effective test is yet un-
proven. This requires further, stronger exploration of the
relative diagnostic accuracies of both tests, and it should be
realized that, despite marked differences in stressor costs,
these costs constitute only a small portion of total perfusion
scintigraphy costs.
Special subgroups. PATIENTS WITH LBBB. The ability of
noninvasive tests to diagnose or localize CAD in patients
with LBBB has been disappointing. Exercise-induced
changes in the ECG are nondiagnostic in the presence of
LBBB (78). Moreover, several scintigraphic studies (espe-
cially when exercise stress is used) have reported false-
positive results for detecting CAD in the left anterior
descending coronary artery in the presence of LBBB (79).
Reports on the use of DSMPI for patients with LBBB are
scarce. Two small studies in respectively 24 and 27 patients
(80,81) reported excellent specificities of 80% and 92% for
detection of disease in the left anterior descending coronary
artery. In another very small study in 19 patients (82),
specificity was dramatically low. It should be noted that in
this latter study, for unclear reasons, exceptionally high
heart rates were achieved, one of the conditions believed to
be related with false positive perfusion defects (79).
PATIENTS WITH LVH. The specificity of exercise electrocar-
diography and scintigraphy to diagnose CAD in patients
with LVH has also been disappointing, even in the absence
of baseline ECG abnormalities (83,84). In one study (13)
specificity for the detection of CAD by DSMPI was indeed
disappointing (59%). In another study (85), however, spec-
ificity was good (85%) and comparable to DSE. Clearly,
Figure 4. Sensitivity, specificity and accuracy of dobutamine stress myocardial perfusion imaging (open bars) versus DSE (solid bars) for detection of CAD.
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further, larger studies are necessary to establish the role of
DSMPI for patients with LBBB and/or LVH.
PATIENTS AFTER MI. The major goals of DSMPI in pa-
tients with a previous MI are (apart from viability issues) to
assess infarct-related coronary artery patency and to identify
patients with multivessel CAD. Only a few studies have
been specifically addressed to these topics. Infarct-related
coronary artery patency was assessed in two studies (86,87).
In one thallium-201 study (86), sensitivity was 71%, and
specificity was 83%; in a technetium-99m study (87),
sensitivity was 44%, and specificity was 82%. The presence
of multivessel CAD for patients with a previous MI should
ideally be based on reversible perfusion defects in two
coronary vascular territories. In three studies (86–88) sen-
sitivity ranged from 14% to 64%, and specificity ranged
from 80% to 100%. An approach in which remote (outside
the infarct-related coronary artery territory) perfusion de-
fects are considered diagnostic for multivessel CAD was
assessed in one study (88); sensitivity was 18% and speci-
ficity was 100%.
PROGNOSTIC VALUE
The prognostic value of DSMPI was assessed in three
studies (from the same institution) in patients with stable
chest pain (28–30), in one study in patients with known
coronary anatomy (31) and in two studies in patients
undergoing vascular surgery (10,32). The largest published
study of patients with stable chest pain involved 392 patients
(mean age 60 6 12 years, 220 men, 190 with a previous
MI) who underwent high-dose dobutamine-atropine
technetium-99m sestamibi single-photon emission com-
puted tomography imaging (29). During a mean follow-up
period of 22 6 13 months, 44 patients (11%) suffered a hard
cardiac event (cardiac death or nonfatal MI), and 78 patients
(20%) suffered any event (hard event or a late revasculariza-
tion procedure). Normal scan results were associated with a
favorable prognosis over the follow-up period with an
annual event rate of 0.8% for hard events and 2.5% for all
events. In contrast, patients with fixed perfusion defects
alone, reversible perfusion defects alone and fixed plus
reversible perfusion defects had a significantly increased
cardiac event rate of 6.8%, 8.1% and 11.6%, respectively, for
hard events and 11.4%, 14.5% and 19.9%, respectively for all
events (Fig. 5). In a multivariate analysis only age, history of
heart failure or typical angina and abnormal scan patterns
were independent predictors of cardiac events. Moreover,
the (for stress level corrected) extent and severity of revers-
ible perfusion defects was an important predictor of events
(Fig. 6). In a study involving 220 of the above described
patients (30), all patients underwent both DSMPI and
DSE. No differences in prognostic value could be detected
between the two imaging modalities. In another very small
study (31) of patients with known coronary anatomy, an
annual event rate of 3% for patients with a normal scan and
44% for patients with reversible perfusion defects was
found. At multivariate analysis the only predictors of events
were a history of previous MI and the extent of reversible
perfusion defects. Unfortunately, the authors did not ana-
lyze whether the extent of reversible perfusion defects had a
better predictive value than coronary anatomy. Two studies
(10,32) described the value of DSMPI for assessing cardiac
risk associated with vascular surgery. Both studies, in
respectively 126 and 142 patients, found a significantly
increased risk for perioperative major cardiac events in
patients with reversible perfusion defects (50% versus 5%
and 19% versus 3%, respectively).
CONCLUSIONS
Despite some theoretical limitations, DSMPI is a safe and
useful nonexercise-dependent stress modality to assess the
Figure 5. Histogram showing the annual event rate for hard events (open bars) and all events (solid bars) according to the MIBI imaging pattern. The
number of patients in each category was 130, 102, 60 and 100, respectively. Reproduced with permission (29).
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presence, localization and extent of CAD and to assess
prognosis. In particular, this stress modality may be of great
value for patients with limited exercise capacity and (rela-
tive) contraindications to dipyridamole or adenosine stress.
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